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Following inﬂammation, primary sensory neurons in the dorsal root ganglion (DRG) alter the production of several proteins.
Most DRG neurons are glutamatergic, using glutaminase as the enzyme for glutamate production, but little is known about
glutaminase following inﬂammation. In the present study, adjuvant-induced arthritis (AIA) was produced in rats with complete
Freund’sadjuvantintothehindpaw.At7daysofAIA,DRGwereexaminedwithglutaminaseimmunohistochemistry,Westernblot
immunoreactivity, and enzyme activity. Image analysis revealed that glutaminase was elevated most in small-sized neurons (21%)
(P < 0.05). Western blot analysis revealed a 19% increase (P < 0.05) in total glutaminase and 21% in mitochondrial glutaminase
(P < 0.05). Glutaminase enzyme activity was elevated 29% (P < 0.001) from 2.20 to 2.83moles/kg/hr. Elevated glutaminase in
primarysensoryneuronscouldleadtoincreased glutamateproductioninspinalprimaryaﬀerentterminalscontributingtocentral
sensitization or in the peripheral process contributing to peripheral sensitization.
1.Introduction
Several animal models of tonic pain, for example, subcuta-
neous and intraarticular injections of inﬂammatory agents
such as complete Freund’s adjuvant (CFA), are used to
mimic human chronic pain [1]. During the acute phase of
inﬂammation, bradykinin, serotonin, prostaglandins, ATP,
H+, and glutamate activate and/or sensitize the aﬀerent
limb of primary sensory neurons by increasing spontaneous
activity, lowering activation threshold, and increasing or
prolonging ﬁring to stimuli [2, 3]. Sensory neurons respond
chronically to inﬂammation by increasing neurotransmit-
ter/neuromodulator, for example, tachykinin (substance P
(SP)) and calcitonin gene-related peptide (CGRP), expres-
sion and content in dorsal root ganglia (DRG) [4–6], and
enhanced immunoreactivity in the spinal dorsal horn [7],
skin, and joints [8, 9]. These peptidergic neurons also are
glutamatergic [10, 11], using glutaminase (GLS) as the syn-
thetic enzyme for neurotransmitter glutamate production
[3, 12]. Despite data regarding functional, morphological,
and neuropeptide alterations in sensory neurons, little is
known about long-term regulation of glutamate production
in tonic pain models.
Acutely, glutamate is released from central primary aﬀer-
ent terminals following noxious stimulation [13–16]. Acute
glutamate release, along with SP and CGRP, is responsible
for sensitization of spinal neurons leading to persistent
or chronic changes [2]. After the induction of knee joint
inﬂammation in monkeys, glutamate-immunoreactive ﬁbers
in the spinal cord increase 30% at 4hr and nearly 40% at2 Pain Research and Treatment
8hr[17]. At 24hrs, extracellular levels of spinal glutamate in
rats are 150% above controls [15] indicating a possible pro-
longed, activity-dependent recruitment of glutamate release
from central primary aﬀerents. These studies suggest that
glutamate production and release is modiﬁed during painful
conditions.
Alteration in glutamate production at these acute and
intermediate time points most likely represents modiﬁcation
in ﬂux control and/or local modiﬁcations of glutamine cycle
enzymes, such as GLS [18, 19]. Longer-term evaluations of
glutamate metabolism have not been performed in tonic
pain models as for neuropeptides in DRG neurons. Based on
previous glutamate studies and evaluations of neuropeptide
production, we hypothesized that persistent inﬂammation
would cause DRG neurons to increase glutaminase produc-
tion. The present study, therefore, was to examine glutami-
nase immunoreactivity and enzyme activity in the rat DRG
at seven days after adjuvant-induced arthritis (AIA).
2.MaterialsandMethods
2.1. Adjuvant-Induced Arthritis. Adult Sprague Dawley male
rats, 250–350g, were used in this study (n = 36). Adjuvant-
induced arthritis was caused in the right hindpaw (n =
20) by the intraplantar injection of 150μLo fc o m p l e t e
Freund’s adjuvant (CFA; Mycobacterium butyricum, Sigma)
emulsiﬁed in saline (1:1) [20]. Controls (n = 16) were na¨ ıve
rats that received no injection. Procedures in this study were
conducted according to guidelines from the International
Association for the Study of Pain [21] and the National
Institutes of Health publication number 80-23 and were
approved by the University of Oklahoma Health Sciences
Center and Oklahoma State University Center for Health
Science Institutional Animal Care and Use Committees.
Eﬀorts were made to minimize the number of animals used
for this study.
The L4 DRG was examined for the following reason. The
tibial nerve innervates the majority of the plantar surface of
the rat hindpaw [22, 23]. Approximately 99% of tibial DRG
neuronal perikarya of rats are located in the L4-L5 DRG and
the L4 DRG contains more than twice the number than L5
[22, 24].
2.2. Behavioral Testing. Two days prior to and for the
days following AIA, rats were tested for pressure sensitivity
with von Frey hairs (Semmes-Weinstein monoﬁlaments;
Stoelting, Inc.). Rats acclimated for ﬁve minutes in a plastic
box (25 × 25 × 25cm) with 6mm holes spaced every
6mm[25]. Monoﬁlaments calibrated for speciﬁc forces were
inserted through the holes underneath to probe the plantar
surface of the hindpaw, 5 times in 3-4-seconds intervals in
diﬀerent places on the plantar surface. Filaments with light
force were used ﬁrst, followed by ﬁlaments of increasing
force. A ﬁlament slowly was applied perpendicularly to the
plantar surface until bending of the ﬁlament occurred. If
the paw did not retract three out of ﬁve times, the next
larger ﬁlament was used. The threshold force was deﬁned as
the ﬁlament (force) that caused the foot retraction without
bending the monoﬁlament three out of ﬁve times. Using
a conversion table for the ﬁlaments (Stoelting), thresholds
were reported as gram force.
Thermal latencies for the footpaw plantar surface were
determined with Plantar Test apparatus (Ugo Basile, Com-
erio, Italy) at an intensity of 55mW/cm2. Rats were placed
on an elevated glass plate (3mm) in clear plastic boxes with
air holes in the lids and acclimated for 10min. Radiant heat
was applied to the plantar surface of the hindpaw and the
withdrawal latency recorded. A second test was followed
after 5min. All behavioral testing occurred at 21-22◦Cw i t h
indirect lighting in the testing room.
2.3. Glutaminase Immunohistochemistry. For immunohisto-
chemical localization of GLS, rats (n = 6A I A7 - d a y ;n =
4 control) were anesthetized with sodium pentobarbital
(90gm/kg) and transcardially perfused with ﬁxative: 0.2%
paraformaldehyde(PFA),70%(v/v)picricacid(PA)in0.1M
phosphate buﬀer, pH 7.4 [26]. Initial immunohistochem-
ical studies had indicated that only small-diameter DRG
neurons were GLS immunoreactive (IR) [27], but subse-
quent studies have determined that high concentrations of
paraformaldehyde mask antigenic sites on GLS and decrease
GLS immunoreactivity [11, 12, 26]. The ﬁxative used in the
current study provides a more accurate immunohistochem-
ical staining pattern with all DRG neurons exhibiting GLS
immunoreactivity [26]. Right L4 DRG were removed and
placed overnight in ﬁxative at 4◦C; the PFA concentration
was increased to 2% for postﬁxation. DRGs were transferred
to 20% sucrose in 0.1M Sorenson’s phosphate buﬀer, pH
7.4 for 24–96hr at 4◦C. The tissue was frozen, sectioned at
20μminacryostat,thawmountedontogelatin-coatedslides,
and dried for 1hr at 37◦C. Every ﬁfth section was used to
reduce the possibility of evaluating a neuron twice. Sections
were washed three times for 10min in phosphate buﬀered
saline (PBS) and incubated in 10% normal goat serum, 10%
normal horse serum, 10% fetal bovine serum, 2% BSA, and
1% polyvinylpyrolidone in PBS with 0.3% Triton (PBS-T).
Sections were incubated for 48hrs at 4◦Ci nr a b -
bit antiglutaminase (1:6000; gift from Dr. N. Curthoys,
Colorado State University, Fort Collins, Colo) in PBS-T.
The tissue was washed three times in PBS and incubated
in biotinylated goat anti-rabbit IgG secondary antibody
(3μg/mL; Vector) in PBS-T for 1hr at room temperature.
Sections were washed two times in PBS following secondary
antibody incubation, washed in sodium carbonate buﬀered
saline (SCBS), pH 8.5, incubated in ﬂuorescein-avidin
(1.5μg/mL; Vector) in SCBS for 1hr, and washed three times
in PBS. Coverslips were apposed with Vectashield mounting
media (Vector) to retard fading of immunoﬂuorescence.
Glutaminase puriﬁed from rat brain was incubated with rab-
bitantiglutaminaseforanabsorptioncontrol.Tissuesections
incubated with absorbed primary antibody were processed
as described above. Other controls included exclusion of
primary and secondary antisera.
Immunoﬂuorescent sections of 7 day AIA and control
DRG were observed with an Olympus Provis AX70 micro-
scope with a 20x objective and digital images were obtained
with a SPOT CCD camera (Diagnostic Instruments). The
entiresectionofDRGwasphotographedinaseriesofimagesPain Research and Treatment 3
and images were saved as uncompressed TIFF ﬁles. The
exposure time for all images was the same for all tissue
sectionsfromallanimals.Theexposuretimewasdetermined
empirically so that weakly stained neurons could be distin-
guished for tracing, but that intensely stained neurons were
not oversaturated [26, 28]. This approach allowed images
to be evaluated along the linear aspect of immunoﬂuores-
cence intensity [28]. The glutaminase-immunoreactive DRG
images were analyzed using the SCION Image program
(Scion Co., Frederick, Md). Only DRG neurons with a
nucleus were evaluated. Individual DRG neurons were cir-
cumscribed and the area, pixel number, and intensity were
recorded. Neuronal cell bodies in the DRG were distributed
into the following three sizes for analysis: 100–600μm2
(small), 600–1200μm2 (medium), and >1200μm2 (large)
[29].
2.4. Glutaminase Enzyme Assay. For GLS enzyme assays, rats
(n = 6A I A ;n = 4 control) were anesthetized (sodium
pentobarbital, 90mg/kg) and decaptitated. Right L4 DRG
were removed quickly, placed in embedding molds with
M-1 mounting media (Lipshaw), and frozen on dry ice.
Individual DRGs were sectioned at −20◦C on a cryostat
at 30μm, sections were placed in aluminum racks for
lyophilization, and samples were stored under vacuum at
−20◦C. The embedding media was removed from around
thelyophilizedDRGsectionsusingaWildHeerbrugg181300
dissecting microscope and DRG sections were weighed using
quartz-ﬁber balances [30–32].
GLS enzyme assay was performed according to Curthoys
and Lowry [33]. Five to six randomly selected DRG sections
from rats with AIA and from control rats were placed
individually in a 40μL volume of reaction mixture con-
taining 20mM glutamine, 100mM K2HPO4,0 . 6m ME D T A ,
0.01% Triton-X 100, 0.01% BSA in 50mM TRIS, pH 8.65,
for 45 minutes at 37◦C. The reaction was stopped by
adding 20μL of 0.7N HCl and placing the samples at 4◦C.
Indicator buﬀer (1mL) containing 300μM ADP, 360μM
NAD, 50μg/mL glutamate dehydrogenase (GDH, rat liver,
Boehringer Mannheim, Indianapolis, Ind) in 50mM TRIS,
pH 8.5 was added for 20 minutes, r.t. In this reaction,
glutamate produced by GLS is converted to 2-oxoglutarate
via GDH with the formation of NADH. Reduction of NAD+
was measured using a ﬂuorometer (Farrand Inc.) with an
excitation wavelength of 365nm and emission at 340nm.
Quantitation was accomplished by reacting increasing con-
centrationsofglutamatestandardsintheindicationreaction.
TheGLSactivityfromeachDRGsectionwasdeterminedand
a mean activity for each DRG was calculated.
2.5. Western Blot for Total Glutaminase. For immunoblot-
ting, rats (n = 5, AIA, control) were killed with CO2 and
decapitated. Right L4 DRG were removed rapidly and homo-
genized [34, 35]. Whole brain, spinal cord and kidney also
were obtained for evaluation. DRG were homogenized indi-
vidually with lysis buﬀer (50mM Tris pH 7.4, 2mM EDTA,
0.05% Triton-X 100) with phosphatase inhibitor cocktail I
and II and protease inhibitor (Sigma). Homogenates were
centrifuged (70,000rpm, 20 minutes) and the protein con-
centration of the supernatant was measured (BCA Protein
Assay Kit, Pierce, Rockford, Ill) to normalize the samples.
Rabbit anti-GLS antibody (gift from Dr. N. Curthoys)
was bound to M-280 Dynabeads (Invitrogen) conjugated
with sheep anti-rabbit antibody [34]. Equal amounts of
total protein (75mg/mL) were exposed to rabbit anti-GLS
antibody beads (16hr, 4◦C) for GLS puriﬁcation [35].
Samples were exposed to a magnet to collect the bead
antibody-protein complex. The puriﬁed protein was eluted
using Laemmli buﬀer (10mM Tris, 1mM EDTA, 2.5% SDS,
5% β-mercaptoethanol, 5% bromophenol blue, pH 8.0) and
by heating the samples at 100◦C for three minutes.
GLS electrophoresis was performed on a 12.5% homoge-
nous polyacrylamide gel (Phast-System, Promega) [34, 35]
along with molecular weight standards (Novagen). Proteins
were transferred to a nitrocellulose membrane in a buﬀer
of 25mM Tris, pH 8.0, 192mM glycine and 20% methanol
at 25mA for 20 minutes. Immunoblotting was performed
using the Protoblot II AP System (Promega) [34, 35].
M e m b r a n e sw e r ed r i e da t3 7 ◦C, rinsed in 20mM Tris-
HCL, 150mM NaCl, and 0.05% Tween 20, pH 7.5 (TBST),
washed in 1% bovine serum albumin (BSA) in TBST, and
incubated in rabbit anti-GLS antibody (1/1000, TBST) for 1
hour at room temperature. Samples were washed in TBST
followed by incubation in alkaline phosphatase conjugated
goat anti-rabbit antibody for 30 minutes. Samples were
washed twice in TBST and TBS. Membranes were incubated
in Western Blue stabilized substrate for alkaline phos-
phatase (Promega; 5-bromo-4-chloro-3-indolyl-phosphate,
nitro blue tetrazolium).
2.6. Mitochondria Isolation for Glutaminase Western Blots.
For mitochondrial isolation, rats (n = 3, AIA, control)
were killed with CO2 and decapitated. Right L4 DRG were
removed rapidly, manually homogenized in a buﬀer contain-
ing 10mM Tris-HCL pH 7.4, 0.32M sucrose, 1mM EDTA.
The supernatant was centrifuged and supernatant (P1) use
for mitochondria isolation. P1 was exposed to a rabbit ant-
porin antibody (Millipore) overnight at 4◦C. Samples were
exposed to a goat anti-rabbit antibody conjugated to M-
500 magnetic beads (Dynal) 30 minutes [36], exposed to a
magnet and reconstituted in a Lysis buﬀer of 50mM Tris-
H C Lp H7 . 4 ,2 m ME D T A ,a n d5 0 μL Triton X-100. The
mitochondria were mechanically separated from the beads
with a Pasteur pipette, the beads removed by a magnet, and
the supernatant (P2; rich in mitochondria) was removed.
Isolated mitochondria (P3) were broken (P4) by freeze
fraction and sonication and a protein assay was performed
on the samples. A normalized concentration of total protein
was used to purify GLS from the mitochondria homogenate
as described above. Gel electrophoresis was performed using
12% gel and separated employing the PhastSystem. Western
blots were performed as described earlier.
Digitizedimages(600dpi)oftheWesternblots(totaland
mitochondrial) were analyzed with Image Tool (UTHSCSA)
to quantify the intensities of GLS bands. Digitized images
were converted to grayscale, inverted, and a shadow north
ﬁlter applied to enhance the contrast between the band and4 Pain Research and Treatment
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(a)
7 day AIA
(b)
Figure 1:Glutaminase(GLS)immunoreactivity(ir)inratL4 dorsalrootganglia(DRG)following7daysofadjuvant-inducedarthritis(AIA)
in the hindpaw. DRG sections were processed simultaneously with a rabbit polyclonal GLS antiserum and photographed under identical
conditions. (a) In control sections, GLS-IR was light to moderate in all neuronal cell sizes, small (long arrows), and medium to large (short
arrows). (b) Elevated GLS-ir in small (long arrows) and medium to large (short arrows) neurons occurred in the DRG following AIA.
background. Bands in each sample were traced separately
with an interactive pen on a Cintiq 21UX (Wacom) tablet.
Eachbandwastracedthreetimestoreducebiasandthemean
calculated for each band.
2.7. Statistics. Data from the analyses are reported as mean
value with standard error of the mean. A Student’s t-test
was used to determine diﬀerences between AIA and control
groups (Prism version 5.01, GraphPad Software Inc., LaJolla,
Calif). In all analyses, P values less than 0.05 were considered
signiﬁcant.
3. Results
Rats developed inﬂammation in the right hindpaw with
redness and edema similar to previous descriptions [1].
Nociceptive responses to normally nonnociceptive pressures
(allodynia) and decreased paw withdrawal latencies to
thermal stimuli (hyperalgesia) were observed in the right
hindpaw from rats with AIA (Table 1).
At 7 days, GLS-immunoreactivity in L4 DRG neurons
from AIA rats was increased over the control DRG neurons
(Figure 1). The GLS-IR intensities of three diﬀerent sizes of
DRG cell bodies, therefore, were analyzed (Figure 2). The
overall GLS-IR intensity of small (<600μm2)L 4 DRG cell
bodies(Figure 2(a))fromtheAIArats(585.6 ±7.7/μm2)was
greater(P<0.01) than controls (484.6 ± 2.0/μm2). This rep-
resenteda21%increaseinsmall-sizedDRGneuronsat7days
AIA compared to control. The GLS-IR intensity of medium-
sized (600–1200μm2)L 4 DRG cell bodies (Figure 2(b))f r o m
the AIA rats (556.9 ± 7.7/μm2)w a sg r e a t e r( P<0.05) than
controls (469.3 ± 4.9/μm2). This represented a 19% increase
inmedium-sizedL4 DRGneuronsat7daysAIAcomparedto
control. The GLS-IR intensity of large (>1200μm2)L 4 DRG
cellbodies (Figure 2(c)) fromthe AIArats (491.0 ± 5.8/μm2)
was greater (P<0.001) than controls (431.6 ± 12.2/μm2).
This represented a 14% increase in large-sized DRG neurons
at 7 days AIA compared to control.
Increased GLS enzyme activity in L4 DRG’s was observed
i nA I Ar a t sc o m p a r e dt oc o n t r o l s( Figure 3). There was a
Table 1: Mechanical and thermal sensitivities.
Days 0 3 7
Pressure
sensitivity (gm)
Control 66.6 ± 5.2 65.8 ± 4.7 64.1 ± 5.3
AIA 61.6 ± 4.4 5.2 ± 0.5∗∗∗ 4.6 ± 0.1∗∗∗
Thermal
sensitivity (sec)
Control 9.5 ± 0.5 7.5 ± 0.6 8.5 ± 0.7
AIA 10.0 ± 0.7 3.2 ± 0.2∗∗∗ 2.9 ± 0.8∗∗∗
Pressure sensitivities determined with von Frey hairs are expressed as gm
force. Pressure and thermal control values for each day were compared with
AIA values with ANOVA. ∗∗∗P<0.0001.
29%increaseinGLSenzymeactivityfromtheAIAcompared
to control DRG. The GLS activity of the AIA rats (2.83 ±
0.30moles/kg/hr) was greater (P<0.05) than controls
(2.20 ± 0.18moles/kg/hr).
Western blots of brain, spinal cord, DRG, and kidney
showed a characteristic, speciﬁc 65kDa band for GLS
(Figure 4)[ 37], as well as a large nonspeciﬁc IgG band
in ∼53kDa range (data not shown) [37]. Analysis of the
rat L4 DRG (Figure 5) showed a signiﬁcant increase (P<
0.05) in the AIA DRG (183.8 ± 11.05) compared to controls
(154.4 ± 10.96; Figure 5). This represented a 19% diﬀerence
between AIA and control DRG. Western blots of the isolated
mitochondria from the L4 DRG demonstrated a band of
65kDa (Figure 6) corresponding to GLS immunoreactivity.
There was a signiﬁcant increase (P<0.05) of GLS-
immunoreactivity in the mitochondria from AIA rats (128±
4.163) compared to controls (100.3±2.404). This represents
a 21% increase in mitochondrial glutaminase concentration
in AIA DRG (Figure 6).
4. Discussion
DRG neuronal cell bodies modify neuropeptide, receptor,
and ion channel production during peripheral inﬂamma-
tion [2]. The current study further illustrates how primary
sensory neurons are altered in regard to glutamate metabo-
lism. In acute inﬂammation, glutamate release increases for
3hrs in the spinal dorsal horn [13–16, 38, 39]. IncreasedPain Research and Treatment 5
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Figure 2: Image analysis of glutaminase (GLS) immunoreactivity (IR) in L4 DRG neurons after 7 days of AIA in the hindpaw. Data are
presented as intensity divided by the area of the cell. DRG neurons were categorized into three area size groups: (a) small: 100–600μm2,
(b) medium: 600–1200μm2,( c )l a r g e :>1200μm2. (a) Small-sized neurons in DRG from AIA rats contained a signiﬁcantly greater GLS
immunoreactive signal (∗∗P<0.01) than controls. (b) Medium-sized neurons in DRG from AIA rats contained a signiﬁcantly greater
immunoreactive signal (∗∗P<0.01) than controls. (c) Large-sized neurons in DRG from AIA rats were more intensely stained than controls
(∗P<0.05).
glutamate-immunoreactivity occurs in the dorsal horn 4–
12hr after AIA induction, but returns to normal levels by
24hrs [17]. In peripheral nerve, glutamate-IR, unmyelinated
and thinly myelinated axons increase in number by 2hrs,
peak between 4 and 6hrs, but return to baseline by 8hrs
[40]. Acute alterations in terminals are likely to be caused
by local ﬂux control mechanisms or allosteric modulation of
glutamine cycle enzymes [18, 19, 41]. Phosphate-activated
GLS [18, 41–43] has several regulatory sites and calcium
(Ca2+) and inorganic phosphate (Pi) are allosteric mod-
ulators of neurotransmitter glutamate levels [42, 43]. A
stimulated nerve terminal during inﬂammation, therefore,6 Pain Research and Treatment
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Figure 3: Glutaminase (GLS) enzyme activity in the L4 DRG at 7
days AIA in the right hindpaw. GLS activity from the DRG of AIA
rats(2.83±0.30moles/kg/hr)waselevated(∗P<0.05)overcontrol
values (2.20 ± 0.18moles/kg/hr).
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Figure 4: This ﬁgure represents the Western blots of glutaminase
within the DRG, brain, spinal cord, and kidney. A characteristic
65kDa band was visualized in all the samples conﬁrming the
speciﬁcity of the antibody and the presence of the kidney/brain
glutaminaseisoformwithinthespinalcordandDRG.Westernblots
have been cropped to exclude the nonspeciﬁc IgG 53kDa band and
enhance the presentation of the 65kDa band.
would increase ATP use causing elevated Pi levels and the
elevated Pi, in turn, would stimulate local GLS activity.
Elevated Ca2+ concentration for synaptic vesicle fusion could
augment the Pi stimulation of GLS [42, 43].
In addition to local mechanisms, the current study
demonstrates an increase in GLS production in the neuronal
cell body during inﬂammation. Increased GLS production
could come from activity-dependent [44] or neurotrophic
mechanisms [28, 45, 46]. The largest GLS increase occurred
in small- and medium-sized DRG cell bodies. Neurons of
these sizes are considered to include nociceptive neurons
with unmyelinated C and lightly myelinated Aδ ﬁbers [2].
Elevated amounts of GLS from the cell body are transported
to axons [47] and are likely to increase production of
glutamate in nociceptor terminals in the spinal cord and
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Figure 5: This ﬁgure represents the Western blot studies of glu-
taminase (GLS) within the L4 DRG from AIA and control rats.
(a) Western blot represents GLS immunoreaction (65kDa) from
the L4 DRG of AIA and control rats. Note the increase of GLS
immunoreaction within the AIA animals. (b) This graph represents
the statistical analysis of the GLS immunoreactivity between AIA
and control rats. A signiﬁcant increase (∗P<0.05) was found
between the AIA rats when compared to controls.
periphery. SP and CGRP occur together with glutamate in
spinal aﬀerent terminals [48] and their corelease generates
hypersensitivity of spinal neurons [2]. We postulate that an
increase in the amount of GLS during chronic inﬂammation
leads to increased production and release of glutamate along
with SP and CGRP [49]. Increased production and release
of these substances could sustain spinal hypersensitivity
maintaining a state of chronic pain.
Increased GLS production could aﬀect the peripheral
terminals also. Glutamate release occurs from peripheral
aﬀerentsandtheseterminalscontainglutamatereceptors[3].
Glutamate receptor agonists sensitize peripheral aﬀerents
and produce nociceptive reﬂexes/hyperalgesia [50, 51]. Dur-
ing inﬂammation, the number of peripheral axons increases
with glutamate receptor immunoreactivity [52]. In chronicPain Research and Treatment 7
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Figure 6: These Western blots represent the mitochondrial glutam-
inase (GLS) immunoreaction (65kDa) within the right L4 DRG. (a)
Note the increase of GLS immunoreaction from the L4 DRG of AIA
and control rats. (b) This graph represents the statistical analysis
of mitochondrial GLS immunoreactivity between AIA and control
rats. A signiﬁcant increase (∗∗P<0.05) was found between the AIA
rats when compared to controls.
inﬂammation, increased glutamate production and release
could activate terminals with elevated number of gluta-
mate receptors leading to ongoing sensitization of primary
aﬀerents [3]. A cycle of increased glutamate production
and release, elevated numbers of axons with glutamate
receptors, and maintenance of sensitization of peripheral
nerve terminals would exacerbate the process of chronic pain
in the periphery.
In the present study, long-term changes due to inﬂam-
mation include an increase in glutaminase in the rat DRG
cellbody.Thisincreasecouldleadtoelevatedproductionand
release of glutamate at both peripheral and central terminals.
An increase in glutamate metabolism in primary sensory
neurons may be partly responsible for heightened nocicep-
tive sensitivity in tonic pain models. Prevention of increased
glutaminaseproductionorinhibitionofglutaminaseenzyme
activity, therefore, may reduce or block some nociceptive
responses during chronic inﬂammation [53].
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